Elixir Medical Corporation
Elixir Medical is dedicated to developing innovative medical devices and technologies to treat cardiovascular and peripheral artery disease. The company focuses on disruptive platforms that improve clinical outcomes and restore vessel function, with a portfolio that includes drug-eluting stent systems, bioresorbable scaffolds, intravascular lithotripsy systems, and vessel restoration technologies. Recognized as one of the World's Most Innovative Companies in 2025 by Fast Company, Elixir Medical continues to lead in innovation, harnessing advanced technologies to transform cardiovascular treatment and improve patient outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
Elixir Medical Corporation
920 N. McCarthy Blvd., Milpitas, CA 95035, USA
Patents
Products
Fully bioresorbable drug-eluting coronary scaffold (thin-strut)
Thin-strut PLLA-based fully bioresorbable coronary scaffold platform with a biodegradable drug-eluting coating and controlled degradation profile intended to provide temporary vessel support and enable vessel remodeling.
Adaptive metallic drug-eluting scaffold (bioadaptive architecture)
Thin-strut metallic drug-eluting scaffold platform incorporating segmented/adaptive architecture and a biodegradable polymer coating intended to allow post-healing mechanical unlocking and restoration of vessel motion and adaptive support.
Balloon-mounted contact-mechanism intravascular lithotripsy catheter
Catheter system with discrete metal contact elements integrated across a semi-compliant balloon surface to generate localized contact stresses that fracture calcified lesions without an external energy source.
Adaptive implant system for below-the-knee (BTK) peripheral arteries
Adaptive metallic implant system engineered for below-the-knee peripheral artery revascularization to provide acute lumen gain and subsequent adaptive support intended to preserve vessel dynamics and improve long-term patency in chronic limb-threatening ischemia.
Fully bioresorbable drug-eluting coronary scaffold (thin-strut)
Thin-strut PLLA-based fully bioresorbable coronary scaffold platform with a biodegradable drug-eluting coating and controlled degradation profile intended to provide temporary vessel support and enable vessel remodeling.
Adaptive metallic drug-eluting scaffold (bioadaptive architecture)
Thin-strut metallic drug-eluting scaffold platform incorporating segmented/adaptive architecture and a biodegradable polymer coating intended to allow post-healing mechanical unlocking and restoration of vessel motion and adaptive support.
Balloon-mounted contact-mechanism intravascular lithotripsy catheter
Catheter system with discrete metal contact elements integrated across a semi-compliant balloon surface to generate localized contact stresses that fracture calcified lesions without an external energy source.
Adaptive implant system for below-the-knee (BTK) peripheral arteries
Adaptive metallic implant system engineered for below-the-knee peripheral artery revascularization to provide acute lumen gain and subsequent adaptive support intended to preserve vessel dynamics and improve long-term patency in chronic limb-threatening ischemia.
Services
Design and management of multicenter randomized controlled trials, single-arm studies and registry-based randomized trials including imaging substudies, independent core-lab analysis and long-term follow-up; collaboration with national registries for large-cohort execution.
Preparation and management of regulatory applications and interactions to support clinical research and market access across jurisdictions, including expedited pathways and national agency submissions.
Cleanroom manufacturing, device assembly, automated coating, inspection and packaging supported by manufacturing engineering, process development and automation to scale clinical supply and commercial production.
Analytical chemistry testing for device materials and coatings including content assays, residual solvent analysis and related chemical characterization to support R&D and regulatory filings.
Development, preclinical testing and clinical evaluation support for balloon-mounted mechanical calcium modification systems designed to fracture vascular calcium and integrate into PCI workflows.
Design and management of multicenter randomized controlled trials, single-arm studies and registry-based randomized trials including imaging substudies, independent core-lab analysis and long-term follow-up; collaboration with national registries for large-cohort execution.
Preparation and management of regulatory applications and interactions to support clinical research and market access across jurisdictions, including expedited pathways and national agency submissions.
Cleanroom manufacturing, device assembly, automated coating, inspection and packaging supported by manufacturing engineering, process development and automation to scale clinical supply and commercial production.
Analytical chemistry testing for device materials and coatings including content assays, residual solvent analysis and related chemical characterization to support R&D and regulatory filings.
Development, preclinical testing and clinical evaluation support for balloon-mounted mechanical calcium modification systems designed to fracture vascular calcium and integrate into PCI workflows.
Expertise Areas
- Bioresorbable scaffold and polymer implant engineering
- Segmented/adaptive scaffold and stent architecture to restore vessel function
- Intravascular lithotripsy and mechanical calcium modification
- Multicenter randomized and registry-based clinical trial management
Key Technologies
- PLLA-based bioresorbable polymer scaffold platforms
- Biodegradable polymer drug-eluting coating systems
- Segmented/adaptive metallic scaffold architectures with mechanical unlocking
- Thin-strut scaffold metallurgy and low-profile strut design
News & Updates
The DESolve Nx trial demonstrated sustained lumen gain, low MACE, and no late stent thrombosis at 36 months, highlighting the long-term safety and efficacy of the bioresorbable scaffold.
The trial showed that the DynamX Bioadaptor met its primary endpoint of target lesion failure at 12 months, with significant reductions in adverse events at six months, supporting its potential to improve PCI outcomes.
Elixir Medical announced CE Mark approval and commercial launch of its LithiX IVL system, designed to treat calcified coronary lesions without external energy, with positive six-month results from the PINNACLE I trial.
The FDA granted Breakthrough Device Designation to the DynamX BTK System for the treatment of below-the-knee vessels impacted by chronic limb-threatening ischemia, supporting its potential to improve outcomes in peripheral artery disease.
Elixir Medical was named to Fast Company's list of the World's Most Innovative Companies in 2025, acknowledging its disruptive technologies and clinical advancements.
The DESolve Nx trial demonstrated sustained lumen gain, low MACE, and no late stent thrombosis at 36 months, highlighting the long-term safety and efficacy of the bioresorbable scaffold.
The trial showed that the DynamX Bioadaptor met its primary endpoint of target lesion failure at 12 months, with significant reductions in adverse events at six months, supporting its potential to improve PCI outcomes.
Elixir Medical announced CE Mark approval and commercial launch of its LithiX IVL system, designed to treat calcified coronary lesions without external energy, with positive six-month results from the PINNACLE I trial.
The FDA granted Breakthrough Device Designation to the DynamX BTK System for the treatment of below-the-knee vessels impacted by chronic limb-threatening ischemia, supporting its potential to improve outcomes in peripheral artery disease.
Elixir Medical was named to Fast Company's list of the World's Most Innovative Companies in 2025, acknowledging its disruptive technologies and clinical advancements.